Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
- PMID: 9367954
- DOI: 10.1126/science.278.5342.1447
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
Abstract
Virus-specific CD4+ T helper lymphocytes are critical to the maintenance of effective immunity in a number of chronic viral infections, but are characteristically undetectable in chronic human immunodeficiency virus-type 1 (HIV-1) infection. In individuals who control viremia in the absence of antiviral therapy, polyclonal, persistent, and vigorous HIV-1-specific CD4+ T cell proliferative responses were present, resulting in the elaboration of interferon-gamma and antiviral beta chemokines. In persons with chronic infection, HIV-1-specific proliferative responses to p24 were inversely related to viral load. Strong HIV-1-specific proliferative responses were also detected following treatment of acutely infected persons with potent antiviral therapy. The HIV-1-specific helper cells are likely to be important in immunotherapeutic interventions and vaccine development.
Comment in
-
How does HIV overcome the body's T cell bodyguards?Science. 1997 Nov 21;278(5342):1399-400. doi: 10.1126/science.278.5342.1399. Science. 1997. PMID: 9411761 No abstract available.
-
Helper CD4+ T cells and HIV-1.Science. 1998 Mar 6;279(5356):1436. doi: 10.1126/science.279.5356.1431g. Science. 1998. PMID: 9508713 No abstract available.
Similar articles
-
Reconstitution of virus-specific CD4 proliferative responses in pediatric HIV-1 infection.J Immunol. 2003 Dec 15;171(12):6968-75. doi: 10.4049/jimmunol.171.12.6968. J Immunol. 2003. PMID: 14662905
-
Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection.J Virol. 1999 Aug;73(8):6715-20. doi: 10.1128/JVI.73.8.6715-6720.1999. J Virol. 1999. PMID: 10400769 Free PMC article.
-
HIV-specific immunity during structured antiviral drug treatment interruption.Vaccine. 2003 Mar 7;21(11-12):1066-71. doi: 10.1016/s0264-410x(02)00610-2. Vaccine. 2003. PMID: 12559781 Clinical Trial.
-
Cellular immune response to human immunodeficiency virus.AIDS. 2001 Feb;15 Suppl 2:S16-21. doi: 10.1097/00002030-200102002-00004. AIDS. 2001. PMID: 11424972 Review.
-
AIDS: decline and fall of immune surveillance?Curr Biol. 1997 Mar 1;7(3):R136-40. doi: 10.1016/s0960-9822(97)70072-1. Curr Biol. 1997. PMID: 9162473 Review.
Cited by
-
Conservation of HIV-1 T cell epitopes across time and clades: validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine.Vaccine. 2012 Dec 14;30(52):7547-60. doi: 10.1016/j.vaccine.2012.10.042. Epub 2012 Oct 24. Vaccine. 2012. PMID: 23102976 Free PMC article.
-
Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells.J Exp Med. 2004 Sep 20;200(6):701-12. doi: 10.1084/jem.20041270. J Exp Med. 2004. PMID: 15381726 Free PMC article.
-
Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection.J Virol. 2001 Nov;75(21):10200-7. doi: 10.1128/JVI.75.21.10200-10207.2001. J Virol. 2001. PMID: 11581388 Free PMC article.
-
Immune reconstitution and viral stimulation are required to restore HIV-specific CD8 T cell responses following advanced infection.J Clin Immunol. 2004 Mar;24(2):115-24. doi: 10.1023/B:JOCI.0000019776.38147.e6. J Clin Immunol. 2004. PMID: 15024178 Clinical Trial.
-
Immune Correlates of Natural HIV Elite Control and Simultaneous HCV Clearance-Supercontrollers.Front Immunol. 2018 Dec 10;9:2897. doi: 10.3389/fimmu.2018.02897. eCollection 2018. Front Immunol. 2018. PMID: 30619267 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials